Tapazoglou E, Kish J, Ensley J, Al-Sarraf M
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201.
Am J Clin Oncol. 1988 Aug;11(4):474-8. doi: 10.1097/00000421-198808000-00013.
Aziridinylbenzoquinone (AZQ), a quinone-containing lipophilic alkylating agent with molecular properties allowing for good penetration through the blood-brain barrier into the central nervous system, was evaluated in a phase II trial for recurrent gliomas patients. Twenty-four patients with computed tomography (CT) scan measurable disease were entered into the trial and received AZQ in doses of a weekly infusion of 15 mg/m2 (group A) and 17.5 mg/m2 (group B). Twenty-two patients were evaluable for both response and toxicity. There were no complete responses in this study. Partial response rates of 23% (3/13) and 11% (1/9) were achieved in group A and group B patients, for a median duration of response of 35 (range 10-106 weeks) and 19 weeks, respectively. The disease was stabilized in five patients from group A and in four patients from group B. Toxicity was mainly hematologic.
氮丙啶基苯醌（AZQ）是一种含醌的亲脂性烷化剂，其分子特性使其能够很好地穿透血脑屏障进入中枢神经系统。在一项针对复发性胶质瘤患者的II期试验中对其进行了评估。24例经计算机断层扫描（CT）可测量疾病的患者进入该试验，分别接受每周输注剂量为15mg/m²（A组）和17.5mg/m²（B组）的AZQ治疗。22例患者可评估疗效和毒性。本研究中无完全缓解病例。A组和B组患者的部分缓解率分别为23%（3/13）和11%（1/9），缓解持续时间中位数分别为35周（范围10 - 106周）和19周。A组有5例患者疾病稳定，B组有4例患者疾病稳定。毒性主要为血液学毒性。
